Your browser doesn't support javascript.
loading
A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization.
Palmer, G M; Tiran, Z; Zhou, Z; Capozzi, M E; Park, W; Coletta, C; Pyriochou, A; Kliger, Y; Levy, O; Borukhov, I; Dewhirst, M W; Rotman, G; Penn, J S; Papapetropoulos, A.
Afiliação
  • Palmer GM; Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine,
  • Tiran Z; Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine,
  • Zhou Z; Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine,
  • Capozzi ME; Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine,
  • Park W; Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine,
  • Coletta C; Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine,
  • Pyriochou A; Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine,
  • Kliger Y; Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine,
  • Levy O; Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine,
  • Borukhov I; Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine,
  • Dewhirst MW; Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine,
  • Rotman G; Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine,
  • Penn JS; Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine,
  • Papapetropoulos A; Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine,
Br J Pharmacol ; 165(6): 1891-1903, 2012 Mar.
Article em En | MEDLINE | ID: mdl-21943108
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos / Neoplasias Colorretais / Neovascularização Retiniana / Inibidores da Angiogênese / Neovascularização Patológica Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Br J Pharmacol Ano de publicação: 2012 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos / Neoplasias Colorretais / Neovascularização Retiniana / Inibidores da Angiogênese / Neovascularização Patológica Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Br J Pharmacol Ano de publicação: 2012 Tipo de documento: Article